GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cogentix Medical Inc (NAS:CGNT) » Definitions » Cash Conversion Cycle

Cogentix Medical (Cogentix Medical) Cash Conversion Cycle : 126.54 (As of Dec. 2017)


View and export this data going back to 1992. Start your Free Trial

What is Cogentix Medical Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Cogentix Medical's Days Sales Outstanding for the three months ended in Dec. 2017 was 45.38.
Cogentix Medical's Days Inventory for the three months ended in Dec. 2017 was 124.11.
Cogentix Medical's Days Payable for the three months ended in Dec. 2017 was 42.95.
Therefore, Cogentix Medical's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2017 was 126.54.


Cogentix Medical Cash Conversion Cycle Historical Data

The historical data trend for Cogentix Medical's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogentix Medical Cash Conversion Cycle Chart

Cogentix Medical Annual Data
Trend Mar08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Dec16 Dec17
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 189.46 178.31 300.51 110.25 133.27

Cogentix Medical Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 134.55 150.80 155.39 161.99 126.54

Competitive Comparison of Cogentix Medical's Cash Conversion Cycle

For the Medical Devices subindustry, Cogentix Medical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogentix Medical's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cogentix Medical's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Cogentix Medical's Cash Conversion Cycle falls into.



Cogentix Medical Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Cogentix Medical's Cash Conversion Cycle for the fiscal year that ended in Dec. 2017 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=48.76+139.37-54.86
=133.27

Cogentix Medical's Cash Conversion Cycle for the quarter that ended in Dec. 2017 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=45.38+124.11-42.95
=126.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cogentix Medical  (NAS:CGNT) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Cogentix Medical Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Cogentix Medical's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogentix Medical (Cogentix Medical) Business Description

Traded in Other Exchanges
N/A
Address
5420 Feltl Road, Minnetonka, MN, USA, 55343
Cogentix Medical Inc is a medical device company. The company designs, develops, manufactures and markets a robust line of high-performance fiberoptic and video endoscopy products under the PrimeSight brand that is used across multiple surgical specialties in diagnostic and treatment procedures. Cogentix offers the Urgent PC Neuromodulation System, a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). It also develops Macroplastique an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily resulting from intrinsic sphincter deficiency.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Brett Reynolds officer: SVP, CFO, Treasurer 5000 W 36TH STREET, MINNEAPOLIS MN 55416
Kenneth A Samet director 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Growth Partners, L.p. 10 percent owner 6 HACHOSHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners Management Ltd. 10 percent owner 6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (gp), L.p. 10 percent owner 6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (agp) Ltd 10 percent owner 6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Cheryl Pegus director 40 RAMLAND ROAD, ORANGEBURG CA 10962
Kenneth H Paulus director 5420 FELTL ROAD, MINNETONKA MN 55343
Sven Wehrwein director
Kevin H Roche director
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010

Cogentix Medical (Cogentix Medical) Headlines

From GuruFocus

Cognyte Announces Changes to its Board of Directors

By Business Wire 07-11-2023